You are here: Industry Insights > neuroblastoma

News List

New Treatment Greatly Boosts Survival for Kids With Aggressive Brain Cancer Drugs
December 13, 2021
Children with the rare cancer neuroblastoma often succumb to the disease despite aggressive treatment. But researchers have found that adding an experimental antibody to that treatment, right off the bat, may improve their outlook.
Safety concerns raised for neuroblastoma candidate drug WorldPharmaNews
November 10, 2021
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.
FDA Grants Accelerated Approval to naxitamab for Neuroblastoma in Bone or Bone Marrow americanpharmaceuticalreview
December 11, 2020
The U.S. Food and Drug Administration (FDA) granted accelerated approval to naxitamab (DANYELZA, Y-mAbs Therapeutics) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients one year of age and older and ...
Algorithm Based on Response, Biology Guides Neuroblastoma Tx drugs
September 06, 2019
Use of a response- and biology-based treatment algorithm for intermediate-risk neuroblastoma is associated with excellent survival and reduces treatment for some patients
Using Zika virus to treat neuroblastoma in children fiercepharma
July 30, 2018
Zika virus is notorious for causing brain defects when passed down from a pregnant woman to her fetus. But researchers at Nemours Children’s Hospital and the University of Central Florida suggest that ....
NICE backs Qarziba for children with high-risk neuroblastoma pharmatimes
July 13, 2018
NHS funding for EUSA’s Pharma’s Qarziba has been approved to treat children with high-risk neuroblastoma.
MabVax Grants Sublicense to Y-mAbs for Neuroblastoma Vaccine americanpharmaceuticalreview
July 11, 2018
MabVax Therapeutics has granted to Y-mAbs Therapeutics an exclusive sublicense to a bi-valent ganglioside based vaccine intended to treat neuroblastoma, a rare pediatric cancer. A third of neuroblastoma patients are diagnosed as infants; and ninety percen
Long-term benefit of Qarziba uncertain, says NICE pharmatimes
May 07, 2018
The National Institute for Health and Care Excellence has ruled against the provision of NHS funding for EUSA Pharma’s neuroblastoma treatment Qarziba.
EUSA Pharma receives EC approval for dinutuximab beta antibody to treat neuroblastoma pharmaceutical-technology
May 11, 2017
EUSA Pharma has secured European Commission (EC) approval for the antibody ch14.18/CHO, (dinutuximab beta) to be used in treating high-risk neuroblastoma in patients older than a year.